Infectious Disease

Treatment de-escalation would reduce adverse events, treatment costs, and the need for virological monitoring.

Top news of the day from across the health care landscape.

The TZA test is faster, more cost-effective, and less labor-intensive than the current test for finding dormant HIV cells.

Gilead plans to file for approval of novel HIV drug in the United States and Europe this year.

HIV-positive individuals are twice as likely to die of smoking than the disease.

Scientists project combining prevention programs could avert up to 40,000 HIV infections over 20 years among injection drug users.

Collaboration is part of a citywide plan to ensure patients with HIV receive care and to reduce the number of new HIV transmissions.

Study provides picture of host cell pathway mobilization to HCV.

Non-EU and EEA countries trail behind in reaching viral suppression target by 2020.

The criminalization of drug use could be detrimental to HIV patient health and does not decrease use, study suggests.

Patient-reported allergy to penicillin antibiotics is a common scenario during health care encounters, with an estimated population prevalence of roughly 8% to 12%.

Investing in diagnostic resources, prevention, and treatment programs are vital to ending the HIV epidemic in the United States.

Top news of the day from across the health care landscape.

The study is the first to demonstrate that CRISPR/Cas9 technology may lead to an HIV cure.

Positivity interventions may influence health outcomes in people living with HIV.

The vending machines dispense kits containing sterile syringes and needles in hopes of reducing the spread of infectious disease.

Predicting the evolution of HIV surface proteins could be used to develop better vaccines.

Hypermutated HIV suppresses immune response.

Glecaprevir/pibrentasvir achieved 99% sustained virologic response rate in patients with chronic HCV with compensated cirrhosis.

Experimental glecaprevir/pibrentasvir treatment shows efficacy across hepatitis C genotypes.

The rise of antibiotic-resistant organisms poses a great threat to national health.

Decline in cancer incidence rates most likely driven by modern antiretroviral therapies.

The final part of a 4-part interview with an infectious disease expert examines the furture treatment landscape and caring for an aging HIV population.

The third of a 4-part interview with an infectious disease expert discusses the impact of specialty drugs and the potential loss of funding to HIV treatment programs.

Regulating emotion may help reduce the risk of HIV spreading among high-risk populations.